초록 ▼

The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1composition of a semi-solid consistency, as well as suitable applicators. The composition comprises pr

The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1composition of a semi-solid consistency, as well as suitable applicators. The composition comprises prostaglandin E1,a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1to C8alcohol, aliphatic C2to C30ester, an aliphatic C8to C30ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

대표청구항 ▼

1. An applicator suitable for placing an effective erection-inducing amount of a semisolid composition into the fossa navicularis of a patient needing treatment, the composition comprising: prostaglandin E1; a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N-s

1. An applicator suitable for placing an effective erection-inducing amount of a semisolid composition into the fossa navicularis of a patient needing treatment, the composition comprising: prostaglandin E1; a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N-substituted amino)-alkanoate, an (N-substituted)-alkanol alkanoate, pharmaceutically acceptable salts thereof and a mixture thereof; a polysaccharide gum; a lipophilic compound which is a member of the group consisting of an aliphatic C1to C8alcohol, an aliphatic C8to C30ester, and a mixture thereof and an acidic buffer system. 2. The applicator of claim 1, wherein the applicator is a single use device and contains a single dose of the semi-solid prostaglandin E1composition. 3. The applicator of claim 1, wherein an amount of the composition of the present invention lacking the active ingredient occupies a position in the applicator between the single dose of the semi-solid prostaglandin E1composition and the applicator tip. 4. The applicator of claim 1, wherein the composition further comprises a vasoactive agent selected from the group consisting of nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, sodium nitroprusside, molsidomine, linsidomine chlorhydrate, S-nitroso-N-acetyl-d,l-penicillamine, phenoxybenzamine, dibenamine, doxazosin, terazosin, phentolamine, tolazoline, prazosin, trimazosin, alfuzosin, tamsulosin, indoramin, acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride, terguride, diazoxide, hydralazine, minoxidil, nimodepine, pinacidil, cyclandelate, dipyridamole, isoxsuprine, chlorpromazine, haloperidol, yohimbine, trazodone, and mixtures thereof. 5. The applicator of claim 1, wherein the polysaccharide gum is a modified galactomannan gum. 6. The applicator of claim 5, wherein the modified galactomannan gum is a modified guar gum. 7. The applicator of claim 1, wherein the lipophilic compound comprises at least one aliphatic C8to C30ester. 8. The applicator of claim 1, wherein the lipophilic compound comprises at least one glyceryl ester selected from the group consisting monoglycerides, diglycerides, triglycerides, and mixtures thereof. 9. The applicator of claim 1, wherein the lipophilic compound comprises at least one glyceryl ester selected from the group consisting of glyceryl monooleate, triolean, trimyristin, tristearin, and mixtures thereof. 10. The applicator of claim 1, wherein the acidic buffer system is capable of providing a buffered pH value for said composition in the range of about 3 to about 6.5. 11. The applicator of claim 1, wherein the composition further comprises an emulsifier selected from the group consisting of sucrose esters, polyoxyethylene sorbitan esters, long chain alcohols, and glyceryl esters. 12. The applicator of claim 1, wherein the emulsifier comprises at least one glyceryl ester selected from the group consisting of glyceryl monooleate, triolean, trimyristin, tristearin, and mixtures thereof. 13. The applicator of claim 1, wherein the composition further comprises a fragrance. 14. The applicator of claim 1, wherein the composition further comprises up to about 5 percent myrtenol, based on the total weight of the composition. 15. The applicator of claim 1, wherein the composition further comprises a preservative. 16. The applicator of claim 1, wherein the composition further comprises a topical anesthetic.